Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple inhaler boost exercise in COPD patients with overinflated lungs?

NCT ID NCT04994574

Symptom relief Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a combination inhaler (tiotropium/olodaterol) can improve exercise capacity in people with COPD who have overinflated lungs. 44 adults used the inhaler for 4 weeks, and researchers measured changes in oxygen use during exercise, heart function, and quality of life. The goal was to see if the treatment helps patients breathe easier and be more active.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

44 people

The number who actually took part.

Started

Aug 2021

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The person who voluntarily signed the consent form 2. Adults over 40 years of age 3. Patients who diagnosed with COPD 4. Patients with smoking history of 10 packs or more 5. Patients who are taking or in need of tiotropium/olodaterol inhaler for the treatment of COPD 6. Patients in a clinically stable state within 3 months of screening 7. Patients who confirmed FEV1/FVC \< 0.7 and FEV1 \<80% after using bronchodilator 8. Patients who confirmed FRC \> 125% 9. Patients who confirmed mMRC \> 2 Exclusion Criteria: 1. Patients with a history of asthma 2. Patients with asthma- COPD overlap 3. Patients with serious disease other than COPD 4. Patients with unstable or life-threatening cardiac arrhythmias 5. Patients hospitalized for heart failure or myocardial infarction within 1 year of screening 6. Patients with systolic ejection fraction less than 40% 7. Patients with unstable ischemic heart disease 8. Patients receiving regular oxygen therapy for 1hour or more per day 9. Others who are difficult to participate in the research under judgment of the investigation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease

Contacts and locations

Locations

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.